UK Medicines Information
New product: Namuscla (mexiletine) 167 mg hard capsules
Information type:
Drug prescribing
Source:
electronic Medicines compendium
Specialities:
Musculo-skeletal disorders | Neurological disorders
Summary
Mexiletine, a sodium channel blocker, is licensed for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. It improves myotonic symptoms by decreasing muscle stiffness through reduction of the delay of muscle relaxation.
UKMi comment
Mexiletine was previously licensed as an anti-arrhythmic and discontinued in the UK in June 2008.
Related links: